✦ LIBER ✦

Malignant pleural mesothelioma: time for translational research – Authors' reply

✍ Scribed by Dean Fennell; Robin Rudd

Book ID: 117783300
Publisher: The Lancet
Year: 2004
Tongue: English
Weight: 108 KB
Volume: 5
Category: Article
ISSN: 1470-2045
DOI: 10.1016/s1470-2045(04)01591-8

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Malignant pleural mesothelioma: time for

Malignant pleural mesothelioma: time for translational research

✍ Alfredo Cesario; Patrizia Russo; Silvia Viaggi; Sonya Trombino; Andrea Imperator 📂 Article 📅 2004 🏛 The Lancet 🌐 English ⚖ 95 KB

MVP and vinorelbine for malignant pleura

MVP and vinorelbine for malignant pleural mesothelioma – Authors' reply

✍ Martin F Muers; Patricia Fisher; Andrew G Nicholson; Richard J Stephens; Mahesh 📂 Article 📅 2008 🏛 The Lancet 🌐 English ⚖ 56 KB

A novel translational approach for human

A novel translational approach for human malignant pleural mesothelioma: heparanase-assisted dual virotherapy

✍ Watanabe, Y; Kojima, T; Kagawa, S; Uno, F; Hashimoto, Y; Kyo, S; Mizuguchi, H; T 📂 Article 📅 2009 🏛 Nature Publishing Group 🌐 English ⚖ 995 KB

Epigenetic Profiles Distinguish Malignan

Epigenetic Profiles Distinguish Malignant Pleural Mesothelioma from Lung Adenocarcinoma

✍ Goto, Y.; Shinjo, K.; Kondo, Y.; Shen, L.; Toyota, M.; Suzuki, H.; Gao, W.; An, 📂 Article 📅 2009 🏛 American Association for Cancer Research 🌐 English ⚖ 1000 KB

In reply to L. Ceresoli et al. “Adjuvant

In reply to L. Ceresoli et al. “Adjuvant radiotherapy for malignant pleural mesothelioma: Challenges and pitfalls”

✍ Tonoli, Sandro; Magrini, Stefano; Tassi, Gianfranco 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 122 KB

A phase II study of gemcitabine in patie

A phase II study of gemcitabine in patients with malignant pleural mesothelioma

✍ Jan P. van Meerbeeck; Paul Baas; Channa Debruyne; Harry J. Groen; Chris Manegold 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 115 KB 👁 2 views

## BACKGROUND. Gemcitabine has shown activity in patients with less chemosensitive solid tumors. Phase II screening of novel drugs is an accepted method with which to investigate new therapies in malignant mesothelioma. The European Organization for Research and Treatment of Cancer-Lung Cancer Coo